胎盘多肽治疗小儿EB病毒感染合并继发性中性粒细胞减少症的疗效及对患儿免疫功能的影响探索  

The Efficacy of Placental Peptides in the Treatment of Secondary Neutropenia in Children with Epstein-Barr Virus Infection and Its Impact on Immune Function

作　　者：韩文雯[1] HAN Wen-wen(Pediatric Digestion Department,Guizhou Provincial People's Hospital,Guiyang Guizhou 550002,China)

机构地区：[1]贵州省人民医院儿科消化,贵州贵阳550002

出　　处：《中华养生保健》2024年第16期42-45,共4页CHINESE HEALTH CARE

摘　　要：目的探索与分析胎盘多肽治疗小儿EB病毒(Epstein Barr Virus,EBV)感染合并继发性中性粒细胞减少症的疗效及对患儿免疫功能的影响。方法选取2022年4月—2023年7月在贵州省人民医院诊治的81例EB病毒感染合并继发性中性粒细胞减少症患儿作为研究对象,根据随机数表法将所有患儿分为胎盘多肽组(n=41)与对照组(n=40)。对照组给予常规药物治疗,胎盘多肽组在对照组治疗的基础上给予胎盘多肽治疗,两组都治疗观察14 d,判定患儿的治疗效果与免疫功能变化情况。结果胎盘多肽组治疗14 d后的总有效率高于对照组,差异有统计学意义(P<0.05)。胎盘多肽组的肝脾增大、发热、咽峡炎、淋巴结肿大等临床症状消失时间短于对照组,差异有统计学意义(P<0.05)。两组治疗14 d后的CD4^(+)T淋巴细胞、CD8^(+)T淋巴细胞相对比例都显著高于治疗前,且胎盘多肽组高于对照组,差异有统计学意义(P<0.05)。两组胎盘多肽组治疗14 d期间的恶心、呕吐、腹泻不良反应发生率比较,差异无统计学意义(P>0.05)。结论胎盘多肽治疗小儿EB病毒感染合并继发性中性粒细胞减少症能提高治疗效果,促进缓解患儿的临床症状,改善患儿的免疫功能,并不会增加不良反应的发生率。Objective To explore and analysis the efficacy of placental peptides in the treatment of secondary neutropenia in children with Epstein-Barr virus infection and their impact on immune function.Method From April 2022 to July 2023,81 cases of EB virus infection combined with secondary neutropenia diagnosed and treated at Guizhou Provincial People's Hospital were selected as the research subjects.Accorded to the random number table method,81 children were divided into the placental peptide group of 41 cases and the control group of 40 cases.The control group were received routine medication treatment,while the placental peptide group were received placental peptide treatment on the basis of the control group.Both groups were treated and observed for 14 days to determine the treatment effect and immune function changes of the children.Result The total effective rates of the placental peptide group after 14 days of treatment were 97.56%,while the control group were 82.50%.The placental peptide group showed a significant improvement compared to the control group(P<0.05).The disappearance time of clinical symptoms such as liver and spleen enlargement,fever,pharyngitis,and lymph node enlargement in the placental peptide group were significantly reduced compared to the control group(P<0.05).After 14 days of treatment,the relative proportion of CD4^(+)T lymphocytes and CD8^(+)T lymphocytes in both groups were significantly higher than before treatment,and the placental peptide group were also higher than those in the control group(P<0.05).The incidence of adverse reactions such as nausea,vomiting and diarrhea during the 14 day treatment period in the placental peptide group were lower(14.63%vs 17.50%),compared with the control group.There were no significant difference between the placental peptide group and the control group(P>0.05).Conclusion The treatment of Epstein-Barr virus infection in children with secondary neutropenia with placental peptides can improve the therapeutic effect,promote the relief of clinical sympto

关 键 词：胎盘多肽 小儿EB病毒 继发性中性粒细胞减少症 免疫功能 不良反应 

分 类 号：R372[医药卫生—病原生物学]